Refine
Year of publication
Has Fulltext
- yes (114)
Is part of the Bibliography
- no (114)
Keywords
- Diffraction (2)
- Elastic scattering (2)
- Polarization (2)
- RHIC (2)
- (Hydroxymethyl)diphenyl(piperidinoalkyl)silanes (1)
- ALK (1)
- Acuris (1)
- Bacterial leakage (1)
- Bipolar disorder (1)
- CAD/CAM crown (1)
Institute
- Frankfurt Institute for Advanced Studies (FIAS) (63)
- Physik (36)
- Medizin (5)
- Biochemie und Chemie (3)
- Biowissenschaften (2)
- Biochemie, Chemie und Pharmazie (1)
- Exzellenzcluster Makromolekulare Komplexe (1)
- MPI für Biophysik (1)
- Senckenbergische Naturforschende Gesellschaft (1)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (1)
We report a measurement of cumulants and correlation functions of event-by-event proton multiplicity distributions from fixed-target Au+Au collisions at sNN−−−√ = 3 GeV measured by the STAR experiment. Protons are identified within the rapidity (y) and transverse momentum (pT) region −0.9<y<0 and 0.4<pT<2.0 GeV/c in the center-of-mass frame. A systematic analysis of the proton cumulants and correlation functions up to sixth-order as well as the corresponding ratios as a function of the collision centrality, pT, and y are presented. The effect of pileup and initial volume fluctuations on these observables and the respective corrections are discussed in detail. The results are compared to calculations from the hadronic transport UrQMD model as well as a hydrodynamic model. In the most central 5\% collisions, the value of proton cumulant ratio C4/C2 is negative, drastically different from the values observed in Au+Au collisions at higher energies. Compared to model calculations including Lattice QCD, a hadronic transport model, and a hydrodynamic model, the strong suppression in the ratio of C4/C2 at 3 GeV Au+Au collisions indicates an energy regime dominated by hadronic interactions.
The STAR Collaboration reports measurements of back-to-back azimuthal correlations of di-π0s produced at forward pseudorapidities (2.6<η<4.0) in p+p, p+Al, and p+Au collisions at a center-of-mass energy of 200 GeV. We observe a clear suppression of the correlated yields of back-to-back π0 pairs in p+Al and p+Au collisions compared to the p+p data. The observed suppression of back-to-back pairs as a function of transverse momentum suggests nonlinear gluon dynamics arising at high parton densities. The larger suppression found in p+Au relative to p+Al collisions exhibits a dependence of the saturation scale, Q2s, on the mass number, A. A linear scaling of the suppression with A1/3 is observed with a slope of −0.09 ± 0.01.
Starting from (MeO)3SiCH2Cl (10) and Ph2(H)SiCH2OH (16), respectively, the (hydroxymethyl)diphenyl(piperidinoalkyl)silanes (HOCH2)Ph2Si(CH2)2NC5H10 (6) and (HOCH2)Ph2Si(CH2)3NC5H10 (8) have been synthesized [10→Ph2(MeO)SiCH2Cl (11)→Ph2(CH2=CH)SiCH2Cl (12)→Ph2(CH2=CH)SiCH2OAc (13)→Ph2(CH2=CH)SiCH2OH (14)→Ph2(CH2=CH)SiCH2OSiMe3 (15)→6; 16→Ph2(H)SiCH2OSiMe3 (17)→8; NC5H10 = piperidino]. N-Quaternization of 6 and 8 with MeI gave the corresponding methiodides 7 and 9, respectively. As shown by IR-spectroscopic studies, compounds 6 and 8 form intramolecular O-H···N hydrogen bonds in solution (CCl4). In the crystal, 6 (space group Pna21; two crystallographically independent molecules) also forms intramolecular O-H···N hydrogen bonds whereas 8 (space group P1̅) forms intermolecular O-H···N hydrogen bonds leading to the formation of centrosymmetric dimers (single-crystal X-ray diffraction studies). The (hydroxymethyl) silanes 6-9 and the related silanols (HO)Ph2Si(CH2)2NC5H 10 (sila-pridinol; 1), sila-pridinol methiodide (2), (HO)Ph2Si(CH2)3NC5H10 (sila-difenidol; 3) and sila-difenidol methiodide (4) were investigated for their antimuscarinic properties. In functional pharmacological experiments as well as in radioligand competition studies, all compounds behaved as simple competitive antagonists at muscarinic M1-, M2-, M3- and M4-receptors. In general, the silanols 1-4 displayed higher receptor affinities (up to 100-fold) than the corresponding (hydroxymethyl) silanes 6-9 . In the (hydroxymethyl)silane series, compound 7 was found to be the most potent muscarinic antagonist [pA2/pKi= 8,71/8,6 (M1), 8,23/7,8 (M2), 8,19/7,8 (M3); pKi = 8,2 (M4)]. In the silanol series, the related compound 2 showed the most interesting antimuscarinic properties [pA2/pKi = 10,37/9,6 (M1), 8,97/8,8 (M2), 9,08/8,8 (M3); pKi = 9,4 (M4)].
The small GTPases H, K, and NRAS are molecular switches indispensable for proper regulation of cellular proliferation and growth. Several mutations in the genes encoding members of this protein family are associated with cancer and result in aberrant activation of signaling processes caused by a deregulated recruitment of downstream effector proteins. In this study, we engineered variants of the Ras-binding domain (RBD) of the C-Raf proto-oncogene, Ser/Thr kinase (CRAF). These variants bound with high affinity with the effector-binding site of Ras in an active conformation. Structural characterization disclosed how the newly identified RBD mutations cooperate and thereby enhance affinity with the effector-binding site in Ras compared with WT RBD. The engineered RBD variants closely mimicked the interaction mode of naturally occurring Ras effectors and acted as dominant-negative affinity reagents that block Ras signal transduction. Experiments with cancer cells showed that expression of these RBD variants inhibits Ras signaling, reducing cell growth and inducing apoptosis. Using these optimized RBD variants, we stratified patient-derived colorectal cancer organoids with known Ras mutational status according to their response to Ras inhibition. These results revealed that the presence of Ras mutations was insufficient to predict sensitivity to Ras inhibition, suggesting that not all of these tumors required Ras signaling for proliferation. In summary, by engineering the Ras/Raf interface of the CRAF-RBD, we identified potent and selective inhibitors of Ras in its active conformation that outcompete binding of Ras-signaling effectors.